12:00 AM
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Fipamezole: Completed Phase IIb enrollment

Santhera completed enrollment of 180 patients in the double-blind, dose-escalation, U.S. and Indian Phase IIb FJORD trial comparing 30, 60 and 90 mg of oral fipamezole vs. placebo for 28...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >